Aberrant expressions of IL-33 and/or ST2 has been well documented in plentiful inflammatory disorders, such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease (37). Here, IL33 is linked to inflammatory bowel disease.